199 related articles for article (PubMed ID: 23508825)
1. Extended pelvic lymph node dissection in prostate cancer: a 20-year audit in a single center.
Abdollah F; Suardi N; Gallina A; Bianchi M; Tutolo M; Passoni N; Fossati N; Sun M; dell'Oglio P; Salonia A; Karakiewicz PI; Rigatti P; Montorsi F; Briganti A
Ann Oncol; 2013 Jun; 24(6):1459-66. PubMed ID: 23508825
[TBL] [Abstract][Full Text] [Related]
2. Performance characteristics of computed tomography in detecting lymph node metastases in contemporary patients with prostate cancer treated with extended pelvic lymph node dissection.
Briganti A; Abdollah F; Nini A; Suardi N; Gallina A; Capitanio U; Bianchi M; Tutolo M; Passoni NM; Salonia A; Colombo R; Freschi M; Rigatti P; Montorsi F
Eur Urol; 2012 Jun; 61(6):1132-8. PubMed ID: 22099610
[TBL] [Abstract][Full Text] [Related]
3. Pelvic lymph node dissection in prostate cancer.
Briganti A; Blute ML; Eastham JH; Graefen M; Heidenreich A; Karnes JR; Montorsi F; Studer UE
Eur Urol; 2009 Jun; 55(6):1251-65. PubMed ID: 19297079
[TBL] [Abstract][Full Text] [Related]
4. Extended versus standard pelvic lymphadenectomy during robot-assisted radical prostatectomy: the role of extended template as an independent predictor of lymph node invasion with comparable morbidity burden.
Mistretta FA; Boeri L; Grasso AA; Lo Russo V; Albo G; DE Lorenzis E; Maggioni M; Palmisano F; Dell'orto P; Bosari S; Rocco B
Minerva Urol Nefrol; 2017 Oct; 69(5):475-485. PubMed ID: 28281741
[TBL] [Abstract][Full Text] [Related]
5. Extent of lymph node dissection improves survival in prostate cancer patients treated with radical prostatectomy without lymph node invasion.
Preisser F; Bandini M; Marchioni M; Nazzani S; Tian Z; Pompe RS; Fossati N; Briganti A; Saad F; Shariat SF; Heinzer H; Huland H; Graefen M; Tilki D; Karakiewicz PI
Prostate; 2018 May; 78(6):469-475. PubMed ID: 29460290
[TBL] [Abstract][Full Text] [Related]
6. Rate and Extent of Pelvic Lymph Node Dissection in the US Prostate Cancer Patients Treated With Radical Prostatectomy.
Nocera L; Sood A; Dalela D; Gild P; Rogers CG; Peabody JO; Montorsi F; Menon M; Briganti A; Abdollah F
Clin Genitourin Cancer; 2018 Apr; 16(2):e451-e467. PubMed ID: 29113771
[TBL] [Abstract][Full Text] [Related]
7. Extended pelvic lymph node dissection in prostate cancer: a 20-year audit in a single center.
Riggs S; Burks RT
Ann Oncol; 2013 Jun; 24(6):1423-4. PubMed ID: 23696615
[No Abstract] [Full Text] [Related]
8. Increasing rate of lymph node invasion in patients with prostate cancer treated with radical prostatectomy and lymph node dissection.
Preisser F; Nazzani S; Bandini M; Marchioni M; Tian Z; Montorsi F; Saad F; Briganti A; Steuber T; Budäus L; Huland H; Graefen M; Tilki D; Karakiewicz PI
Urol Oncol; 2018 Aug; 36(8):365.e1-365.e7. PubMed ID: 29887241
[TBL] [Abstract][Full Text] [Related]
9. Assessing the risk of lymph node invasion in patients with intermediate risk prostate cancer treated with extended pelvic lymph node dissection. A novel prediction tool.
Briganti A; Capitanio U; Abdollah F; Gallina A; Suardi N; Bianchi M; Tutolo M; Salonia A; Freschi M; Rigatti P; Montorsi F
Prostate; 2012 Apr; 72(5):499-506. PubMed ID: 22468270
[TBL] [Abstract][Full Text] [Related]
10. Surgeon-led prostate cancer lymph node staging: pathological outcomes stratified by robot-assisted dissection templates and patient selection.
Altok M; Babaian K; Achim MF; Achim GC; Troncoso P; Matin SF; Chapin BF; Davis JW
BJU Int; 2018 Jul; 122(1):66-75. PubMed ID: 29446205
[TBL] [Abstract][Full Text] [Related]
11. Topography of lymph node metastases in prostate cancer patients undergoing radical prostatectomy and extended lymphadenectomy: results of a combined molecular and histopathologic mapping study.
Heck MM; Retz M; Bandur M; Souchay M; Vitzthum E; Weirich G; Mollenhauer M; Schuster T; Autenrieth M; Kübler H; Maurer T; Thalgott M; Herkommer K; Gschwend JE; Nawroth R
Eur Urol; 2014 Aug; 66(2):222-9. PubMed ID: 23465520
[TBL] [Abstract][Full Text] [Related]
12. Outcomes after radical prostatectomy for patients with clinical stages T1-T2 prostate cancer with pathologically positive lymph nodes in the prostate-specific antigen era.
Dorin RP; Lieskovsky G; Fairey AS; Cai J; Daneshmand S
Urol Oncol; 2013 Nov; 31(8):1441-7. PubMed ID: 22516714
[TBL] [Abstract][Full Text] [Related]
13. Predictors of Lymph Node Invasion in Patients with Clinically Localized Prostate Cancer Who Undergo Radical Prostatectomy and Extended Pelvic Lymph Node Dissection: The Role of Obesity.
Tafuri A; Rizzetto R; Amigoni N; Sebben M; Shakir A; Gozzo A; Odorizzi K; Gallina S; Bianchi A; Ornaghi P; Brunelli M; Migliorini F; Cerruto MA; Artibani W; Siracusano S; Antonelli A; Porcaro AB
Urol Int; 2021; 105(5-6):362-369. PubMed ID: 33059351
[TBL] [Abstract][Full Text] [Related]
14. External validation of the updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection.
Gacci M; Schiavina R; Lanciotti M; Masieri L; Serni S; Vagnoni V; Abdollah F; Carini M; Martorana G; Montorsi F
Urol Int; 2013; 90(3):277-82. PubMed ID: 23296120
[TBL] [Abstract][Full Text] [Related]
15. Indication for and extension of pelvic lymph node dissection during robot-assisted radical prostatectomy: an analysis of five European institutions.
Suardi N; Larcher A; Haese A; Ficarra V; Govorov A; Buffi NM; Walz J; Rocco B; Borghesi M; Steuber T; Pini G; Briganti A; Mottrie AM; Guazzoni G; Montorsi F; Pushkar D; Van Der Poel H;
Eur Urol; 2014 Oct; 66(4):635-43. PubMed ID: 24411992
[TBL] [Abstract][Full Text] [Related]
16. Adherence to pelvic lymph node dissection recommendations according to the National Comprehensive Cancer Network pelvic lymph node dissection guideline and the D'Amico lymph node invasion risk stratification.
Leyh-Bannurah SR; Budäus L; Zaffuto E; Pompe RS; Bandini M; Briganti A; Montorsi F; Schiffmann J; Shariat SF; Fisch M; Chun F; Huland H; Graefen M; Karakiewicz PI
Urol Oncol; 2018 Feb; 36(2):81.e17-81.e24. PubMed ID: 29248430
[TBL] [Abstract][Full Text] [Related]
17. The extent of pelvic lymph node dissection correlates with the biochemical recurrence rate in patients with intermediate- and high-risk prostate cancer.
Schiavina R; Manferrari F; Garofalo M; Bertaccini A; Vagnoni V; Guidi M; Borghesi M; Baccos A; Morselli-Labate AM; Concetti S; Martorana G
BJU Int; 2011 Oct; 108(8):1262-8. PubMed ID: 21446934
[TBL] [Abstract][Full Text] [Related]
18. More extensive pelvic lymph node dissection improves survival in patients with node-positive prostate cancer.
Abdollah F; Gandaglia G; Suardi N; Capitanio U; Salonia A; Nini A; Moschini M; Sun M; Karakiewicz PI; Shariat SF; Montorsi F; Briganti A
Eur Urol; 2015 Feb; 67(2):212-9. PubMed ID: 24882672
[TBL] [Abstract][Full Text] [Related]
19. Identifying candidates for super-extended staging pelvic lymph node dissection among patients with high-risk prostate cancer.
Gandaglia G; Zaffuto E; Fossati N; Bandini M; Suardi N; Mazzone E; Dell'Oglio P; Stabile A; Freschi M; Montorsi F; Briganti A
BJU Int; 2018 Mar; 121(3):421-427. PubMed ID: 29063734
[TBL] [Abstract][Full Text] [Related]
20. Adherence of the indication to European Association of Urology guideline recommended pelvic lymph node dissection at a high-volume center: Differences between open and robot-assisted radical prostatectomy.
Schiffmann J; Haese A; Leyh-Bannurah SR; Salomon G; Steuber T; Schlomm T; Boehm K; Beyer B; Larcher A; Michl U; Heinzer H; Huland H; Graefen M; Karakiewicz PI
Eur J Surg Oncol; 2015 Nov; 41(11):1547-53. PubMed ID: 26117216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
